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Abstract
Most patients suffering from cancer die of metastatic
disease. Surgical removal of solid tumors is performed
as an initial attempt to cure patients if the primary
tumor meets surgical indications. However, it is possible
that surgical trauma itself influences the development of
early recurrence. First, resection handling of the tumor
can provoke detachment of tumor cells. Second, surgical
trauma provokes the severe inflammatory reaction.
Vascular inflammation is considered to render the
endothelium adhesive to circulating tumor cells thereby
allowing the metastasis of tumor cells. We have pre-
viously reported that administration of atrial natriuretic
peptide (ANP) during the perioperative period reduces
inflammatory response and has a prophylactic effect on
postoperative cardiopulmonary complications in lung
cancer surgery. Here we demonstrate that cancer recur-
rence after curative surgery was significantly lower in
ANP-treated patients than in control patients (surgery
alone). ANP is known to bind specifically to guanylyl
cyclase-A (GC-A) receptor. In mouse models, we found
that metastasis of GC-A–non-expressing tumor cells
(i.e., B16 mouse melanoma cells) to the lung was
increased in vascular endothelium-specificGC-A knock-
out mice and decreased in vascular endothelium-specific
GC-A transgenic mice compared with control mice.
ANP inhibited the adhesion of cancer cells to human
pulmonary artery endothelial cells by suppressing the
E-selectin expression that is promoted by inflammation.
These results suggest that ANP prevents cancer metas-
tasis by inhibiting the adhesion of tumor cells to
inflamed endothelial cells. Thus, we have planned to
start a multicenter randomized clinical trial to examine
the use of perioperative administration of ANP for the
prevention of cancer recurrence after lung cancer sur-
gery in this year. In the near future, we want to expand
the adaptation of ANP for various types of cancer
surgery.
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